BIXT — Bioxytran, Inc. Company Overview

Executive Summary

Bioxytran, Inc. is a Nevada-incorporated, clinical-stage pharmaceutical company trading over-the-counter under the symbol BIXT. The company emerged from a September 2018 reverse merger with America's Driving Ranges, Inc. and is led by CEO/Chairman David Platt, Ph.D. Bioxytran is developing two distinct therapeutic platforms: BXT-25, a synthetic oxygen-carrying molecule for ischemic stroke, and ProLectin-Rx, a galectin-antagonist antiviral franchise aimed primarily at COVID-19 and related lung fibrosis/ARDS indications. As of September 2026, the company's market capitalization stood at roughly $2.4 million with shares trading near $0.02, down nearly 64% year-over-year — a valuation that reflects a pre-revenue biotech with acute financing needs and no FDA-approved products.

Core Business Model

Bioxytran does not intend to build its own commercial infrastructure. Management has stated its strategy is to advance drug candidates through early-to-mid-stage clinical development and then license or partner the assets to larger pharmaceutical companies rather than pursue independent manufacturing and sales. The company funds its operations almost entirely through dilutive capital raises — convertible notes and equity issuances — and has kept overhead minimal, with the CEO and CFO drawing $35,000 monthly salaries and the Chief Communications Officer $26,215, with all three voluntarily taking 50% pay cuts during 2024 to conserve cash.

Business Segments

Bioxytran operates as a single pharmaceutical R&D business organized through several subsidiaries: Pharmalectin, Inc. (Delaware, houses the ProLectin antiviral franchise), Pharmalectin (BVI) (British Virgin Islands IP holding entity), Pharmalectin India (clinical operations), and NDPD Pharma, Inc., acquired in October 2024 to bring in polysaccharide-based patents targeting SARS-CoV-2. There is no meaningful segment reporting given the company has no commercial revenue.

Product Portfolio

• BXT-25: An intravenous, bovine-hemoglobin-derived oxygen-carrying molecule stabilized with a co-polymer, described by the company as roughly 5,000 times smaller than a human red blood cell, targeting ischemic stroke. The program remains preclinical; a successful animal study in Swiss Albino mice was announced in April 2023, with 14-day repeated-dose toxicity studies planned as the next step.
• ProLectin-M: Oral galectin antagonist for mild-to-moderate COVID-19; FDA cleared IND #153742 in August 2023 for the "PROTECT" trial, and India's CDSCO approved a Phase 1b/2a IND in December 2022.
• ProLectin-I: IV formulation for severe COVID-19 cases; CDSCO IND approval in January 2023.
• ProLectin-F: Targets lung fibrosis.
• ProLectin-A: Combines the polysaccharide and hemoglobin technologies for ARDS treatment.

Both PROTECT and the India trials were expected to begin in Q2 2025, contingent on funding — a qualifier that has recurred across company disclosures.

Competitive Landscape

In stroke, the standard of care — tissue plasminogen activator (tPA) and mechanical thrombectomy — is entrenched, well-reimbursed, and backed by major device makers; synthetic oxygen-carrier therapeutics have a troubled history in the space (prior hemoglobin-based oxygen carriers from other developers have struggled to reach approval), meaning BXT-25 faces both scientific and regulatory skepticism. In COVID-19 therapeutics, Pfizer's Paxlovid and Merck's Lagevrio are the entrenched FDA-approved oral options; Bioxytran's ProLectin platform is differentiated by mechanism (galectin antagonism rather than protease/polymerase inhibition) but has no approved product and a fraction of the capital of its rivals. The company frames its total addressable stroke market at roughly $50 billion, citing Global Industry Analysts, Inc., but has not translated this into any near-term revenue opportunity.

Strategic Strengths & Risks

Strengths: Bioxytran has secured multiple regulatory green lights (FDA IND, multiple CDSCO INDs) that at least demonstrate some ability to clear early regulatory hurdles; its dual-platform approach (hypoxia and antiviral) diversifies scientific risk across two large addressable markets; and the 2024 NDPD Pharma acquisition added patent assets at low apparent cost.

Risks: The risks dominate the picture. The company disclosed roughly $948,642 in outstanding convertible note principal as of December 31, 2024, and estimates it needs $30–35 million in aggregate to complete its pipeline (versus ~$5 million invested in ProLectin to date) — an enormous funding gap relative to a $2.4 million market cap. Going-concern language, OTC-market illiquidity, repeated trial-timeline slippage ("pending funding"), and a tiny core team all point to elevated dilution and execution risk. There is no product revenue and no near-term path to any.

Financial Overview

Bioxytran has no product revenue. Convertible note principal outstanding was approximately $948,642 as of year-end 2024. Aggregate program funding needs are estimated at $30–35 million (ProLectin-Rx: $23–30 million; ProLectin-A: ~$12 million; BXT-25: ~$5.2 million), against roughly $5 million invested in ProLectin to date. As of September 2026, market capitalization was approximately $2.41 million with the stock trading around $0.02 per share, down about 64% over the trailing year — reflecting the market's assessment of the company's severe capital constraints.

Summary Conclusion

Bioxytran is a speculative micro-cap biotech with scientifically interesting but clinically unproven early-stage assets in stroke and antiviral therapeutics. The gap between its stated capital needs ($30–35 million) and its actual market value (~$2.4 million) underscores extreme dilution risk, and the absence of any approved product or revenue stream leaves the company with essentially no economic moat today. Any investment thesis rests entirely on binary clinical and regulatory catalysts years away from commercialization.